Prostate-Specific Membrane Antigen-Targeted Turn-on Probe for Imaging Cargo Release in Prostate Cancer Cells

被引:9
|
作者
Olatunji, Feyisola P. [1 ]
Savoy, Emily A. [1 ]
Panteah, Mylan [2 ]
Mesbahi, Nooshin [1 ]
Abbasi, Armina [1 ]
Talley, Cresencia M. [1 ]
Lovingier, Christine L. [1 ]
Caromile, Leslie A. [2 ]
Berkman, Clifford E. [1 ]
机构
[1] Washington State Univ, Dept Chem, Pullman, WA 99164 USA
[2] UCONN Hlth Ctr Vasc Biol, Farmington, CT 06030 USA
基金
美国国家卫生研究院;
关键词
MONOCLONAL-ANTIBODY; FOLATE HYDROLASE; TUMOR-CELLS; PH; INHIBITOR; PSMA; PET; INTERNALIZATION; THERAPY; APTAMER;
D O I
10.1021/acs.bioconjchem.1c00435
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The tunable nature of phosphoramidate linkers enables broad applicability as pH-triggered controlled-release platforms, particularly in the context of antibody-and small-molecule-drug conjugates (ADCs and SMDCs), where there remains a need for new linker technology. Herein, we explored in-depth the release of turn-on fluorogenic payloads from a homoserinyl-based phosphoramidate acid-cleavable linker. Kinetics of payload release from the scaffold was observed in buffers representing the pH conditions of systemic circulation, early and late endosomes, and lysosomes. It was found that payload release takes place in two key consecutive steps: (1) P-N bond hydrolysis and (2) spacer immolation. These two steps were found to follow pseudo-first-order kinetics and had opposite dependencies on pH. P-N bond hydrolysis increased with decreasing pH, while spacer immolation was most rapid at physiological pH. Despite the contrasting release kinetics of these two steps, maximal payload release was observed at the mildly acidic pH (5.0-5.5), while minimal payload release occurred at physiological pH. We integrated this phosphoramidate-payload linker system into a PSMA-targeted fluorescent turn-on probe to study the intracellular trafficking and release of a fluorescent payload in PSMA-expressing prostate cancer cells. Results showed excellent turn-on and accumulation of the coumarin payload in the late endosomal and lysosomal compartments of these cells. The release properties of this linker mark it as an attractive alternative in the modular design of ADCs and SMDCs, which demand selective intracellular payload release triggered by the pH changes that accompany intracellular trafficking.
引用
收藏
页码:2386 / 2396
页数:11
相关论文
共 50 条
  • [11] Prostate-specific membrane antigen targeted PET imaging for prostate cancer recurrence
    Ferdinandus, Justin
    Fendler, Wolfgang Peter
    Hadaschik, Boris
    Herrmann, Ken
    CURRENT OPINION IN UROLOGY, 2020, 30 (05) : 635 - 640
  • [12] Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer
    Stuparu, Andreea D.
    Capri, Joseph R.
    Meyer, Catherine A. L.
    Le, Thuc M.
    Evans-Axelsson, Susan L.
    Current, Kyle
    Lennox, Mark
    Mona, Christine E.
    Fendler, Wolfgang P.
    Calais, Jeremie
    Eiber, Matthias
    Dahlbom, Magnus
    Czernin, Johannes
    Radu, Caius G.
    Lueckerath, Katharina
    Slavik, Roger
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (07) : 989 - 995
  • [13] A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer
    Henry, MD
    Wen, SH
    Silva, MD
    Chandra, S
    Milton, M
    Worland, PJ
    CANCER RESEARCH, 2004, 64 (21) : 7995 - 8001
  • [14] Prostate-Specific Membrane Antigen-Targeted Therapy in Prostate Cancer: History, Combination Therapies, Trials, and Future Perspective
    Mattana, Francesco
    Muraglia, Lorenzo
    Barone, Antonio
    Colandrea, Marzia
    Diffalah, Yasmina Saker
    Provera, Silvia
    Cascio, Alfio Severino
    Sale, Emanuela Omodeo
    Ceci, Francesco
    CANCERS, 2024, 16 (09)
  • [15] Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy
    Arsenault, Frederic
    Beauregard, Jean-Mathieu
    Pouliot, Frederic
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2018, 12 (03) : 359 - 365
  • [16] Prostate-Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer
    Meher, Niranjan
    Ashley, Gary W.
    Bobba, Kondapa Naidu
    Wadhwa, Anju
    Bidkar, Anil P.
    Dasari, Chandrashekhar
    Mu, Changhua
    Sankaranarayanan, Ramya Ambur
    Serrano, Juan A. Camara
    Raveendran, Athira
    Bulkley, David P.
    Aggarwal, Rahul
    Greenland, Nancy Y.
    Oskowitz, Adam
    Wilson, David M.
    Seo, Youngho
    Santi, Daniel V.
    Vanbrocklin, Henry F.
    Flavell, Robert R.
    ADVANCED HEALTHCARE MATERIALS, 2024, 13 (19)
  • [17] The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging
    Cho, Hae Lin
    Perni, Subha
    D'Amico, Anthony V.
    Yamoah, Kosj
    Dee, Edward Christopher
    PROSTATE CANCER AND PROSTATIC DISEASES, 2023, 26 (03) : 511 - 515
  • [18] Prostate-Specific Membrane Antigen-Targeted Imaging and Its Correlation with HOXB13 Expression
    Angappulige, Duminduni Hewa
    Barashi, Nimrod S.
    Pickersgill, Nicholas
    Weimholt, Cody
    Luo, Jingqin
    Shadmani, Ghazal
    Tarcha, Ziad
    Rayamajhi, Sampanna
    Mahajan, Nupam P.
    Andriole, Gerald L.
    Siegel, Barry A.
    Kim, Eric H.
    Mahajan, Kiran
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (08) : 1210 - 1216
  • [19] Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals in Diagnosis and Therapy of Prostate Cancer: Current Status and Future Perspectives
    Lin, Mai
    Ta, Robert T.
    Kairemo, Kalevi
    Le, Dao B.
    Ravizzini, Gregory C.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2021, 36 (03) : 237 - 251
  • [20] The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging
    Hae Lin Cho
    Subha Perni
    Anthony V. D’Amico
    Kosj Yamoah
    Edward Christopher Dee
    Prostate Cancer and Prostatic Diseases, 2023, 26 : 511 - 515